Updated Austrian treatment algorithm in HER2+ metastatic breast cancer

被引：0
|
作者：
Rupert Bartsch
Simon Peter Gampenrieder
Gabriel Rinnerthaler
Edgar Petru
Daniel Egle
Andreas Petzer
Marija Balic
Ursula Pluschnig
Thamer Sliwa
Christian Singer
机构：
[1] Medical University of Vienna,Department of Medicine I, Division of Oncology
[2] Paracelsus Medical University Salzburg,Third Medical Department with Hematology and Medical Oncology, Hemostaseology, Rheumatology and Infectious Diseases, Oncologic Center
[3] Medical University of Graz,University Hospital for Gynecology and Obstetrics, Clinical Department of Gynecology
[4] Medical University of Innsbruck,Department of Gynecology, Breast Cancer Center Tirol
[5] Ordensklinikum Linz GmbH,Barmherzige Schwestern, Elisabethinen, Department of Internal Medicine I for Hematology with Stem Cell Transplantation, Hemostaseology and Medical Oncology
[6] Medical University of Graz,Department of Internal Medicine, Division of Clinical Oncology
[7] Klagenfurt Hospital,Department of Internal Medicine and Hematology and Internal Oncology
[8] Hanusch Hospital,3rd Medical Department, Hematology and Oncology
[9] Medical University of Vienna,Department of Gynecology, Breast Cancer Center Vienna
来源：
Wiener klinische Wochenschrift | 2022年 / 134卷
关键词：
HER2; Trastuzumab; Pertuzumab; Antibody-conjugate; Tyrosin-kinase inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
A group of Austrian breast cancer specialists met in December 2020 to establish a comprehensive clinical benefit-risk profile of available HER2-targeted therapies based on recent data and to develop an updated treatment algorithm by consensus over several months in 2021. A total of four scenarios were developed in which treatment strategies appropriate for specific patient profiles were evaluated. Consensus was established by detailed discussions of each scenario and by reaching full consensus.
引用
收藏
页码：63 / 72
页数：9
相关论文
共 50 条
  • [31] Targeting Glucose Metabolism in HER2+ Breast Cancer
    Telang, Sucheta
    Chang, Simone
    Burlison, Joseph
    FASEB JOURNAL, 2021, 35
  • [32] Efficacy, patterns of use and cost of Pertuzumab in the treatment of HER2+ metastatic breast cancer in Singapore: The National Cancer Centre Singapore experience
    Rahardja, Sylwan
    Tan, Ryan Ying Cong
    Sultana, Rehena
    Leong, Fun Loon
    Lim, Elaine Hsuen
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2020, 11 (03):
  • [33] Clinical predictors of long-term survival in Her2-positive (HER2+) metastatic breast cancer (MBC)
    Murthy, Pooja
    Kidwell, Kelley M.
    Thomas, Dafydd G.
    Griggs, Jennifer J.
    Merajver, Sofia D.
    Schott, Anne F.
    Smerage, Jeffrey B.
    Van Poznak, Catherine H.
    Wicha, Max
    Hayes, Daniel F.
    Henry, N. Lynn
    CANCER RESEARCH, 2015, 75
  • [34] B-cells and regulatory T-cells in the microenvironment of HER2+ breast cancer are associated with decreased survival: a real-world analysis of women with HER2+ metastatic breast cancer
    Tessa G. Steenbruggen
    Denise M. Wolf
    Michael J. Campbell
    Joyce Sanders
    Sten Cornelissen
    Bram Thijssen
    Roberto A. Salgado
    Christina Yau
    Nick O-Grady
    Amrita Basu
    Rajith Bhaskaran
    Lorenza Mittempergher
    Gillian L. Hirst
    Jean-Philippe Coppe
    Marleen Kok
    Gabe S. Sonke
    Laura J. van ‘t Veer
    Hugo M. Horlings
    Breast Cancer Research, 25
  • [35] registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Tripathy, D.
    Kaufman, P.
    Brufsky, A.
    Mayer, M.
    Yood, M.
    Wang, L.
    Brammer, M.
    Yardley, D.
    Tan-Chiu, E.
    Rugo, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer.
    Loft, Matthew
    Lok, Sheau Wen
    De Boer, Richard H.
    Malik, Laeeq
    Greenberg, Sally
    Yeo, Belinda
    Anton, Angelyn
    Nott, Louise M.
    Richardson, Gary Edward
    Collins, Ian M.
    Torres, Javier
    Barnett, Frances Sarah
    Devitt, Bianca Alix
    Gibbs, Peter
    Gately, Lucy
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Treatment of early-stage HER2+ breast cancer-an evolving field
    Ferreira, Arlindo R.
    Saini, Kamal S.
    Metzger-Filho, Otto
    ECANCERMEDICALSCIENCE, 2015, 9
  • [38] The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
    Janiszewska, Michalina
    Stein, Shayna
    Filho, Otto Metzger
    Eng, Jennifer
    Kingston, Natalie L.
    Harper, Nicholas W.
    Rye, Inga H.
    Aleckovic, Masa
    Trinh, Anne
    Murphy, Katherine C.
    Marangoni, Elisabetta
    Cristea, Simona
    Oakes, Benjamin
    Winer, Eric P.
    Krop, Ian
    Russnes, Hege G.
    Spellman, Paul T.
    Bucher, Elmar
    Hu, Zhi
    Chin, Koei
    Gray, Joe W.
    Michor, Franziska
    Polyak, Kornelia
    JCI INSIGHT, 2021, 6 (11)
  • [39] Oral Ridaforolimus Plus Trastuzumab for Patients With HER2+ Trastuzumab-Refractory Metastatic Breast Cancer
    Seiler, Milton
    Ray-Coquard, Isabelle
    Melichar, Bohuslav
    Yardley, Denise A.
    Wang, Rui X.
    Dodion, Pierre F.
    Lee, Mark A.
    CLINICAL BREAST CANCER, 2015, 15 (01) : 60 - 65
  • [40] Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis
    Abby B. Statler
    Brian P. Hobbs
    Wei Wei
    Annie Gupta
    Cassann N. Blake
    Zeina A. Nahleh
    Scientific Reports, 9
12345